2Salih W, Schembri S, Chalmers JD. Simplification of the IDSA/ ATS criteria for severe CAP using meta-analysis and observational data[J]. Eur Respir J, 2014, 43(3) : 842-851. DOI: 10. 1183/ 09031936. 00089513.
3Cao B, Zhao C J, Yin YD, et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China [ J ]. Clin Infect Dis, 2010, 51 (2) : 189-194. DOI: 10. 1086/653535.
4Liu Y, Chen M, Zhao T, et al. Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population[ J]. BMC Infect Dis, 2009, 9: 31. DOI: 10. 1186/1471-2334-9-31.
5Von Baum H, Wehe T, Marre R, et al. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa : Diagnosis, incidence and predictors [ J ]. Eur Respir J, 2010, 35 (3): 598-605. DOI: 10. 1183/09031936. 00091809.
6Einhorn AE, Neuhauser MM, Bearden DT, et al. Extended- spectrum beta-laetamases: frequency, risk factors, and outcomes [ J]. Pharmacotherapy, 2002, 22(1 ): 14-20.
8Qu JX, Gu L, Pu ZH, et al. Viral etiology of community-acquired pneumonia among adolescents and adults with mild or moderate severity and its relation to age and severity[ J]. BMC Infect Dis, 2015, 15: 89. DOI: 10. 1186/s12879-015-0808-0.
9Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection[J]. N Engl J Med, 2013, 368(24) : 2277-2285. DOI: 10. 1056/NEJMoa1305584.
10Ruuskanen O, Lahti E, Jennings LC, et al. Viral pneumonia [J]. Lancet, 2011, 377(9773): 1264-1275. DOI: 10. 1016/ S0140-6736 ( 10)61459-61456.
